Xeris Biopharma Holdings, Inc. (XERS)
9.08
-0.17
(-1.84%)
USD |
NASDAQ |
Oct 02, 16:00
9.085
0.00 (0.00%)
Pre-Market: 20:00
Xeris Biopharma Holdings Net Income (Quarterly) : -31.10M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.10M |
| March 31, 2026 | 2.234M |
| December 31, 2025 | 11.08M |
| September 30, 2025 | 0.621M |
| June 30, 2025 | -1.928M |
| March 31, 2025 | -9.22M |
| December 31, 2024 | -5.113M |
| September 30, 2024 | -15.74M |
| June 30, 2024 | -15.00M |
| March 31, 2024 | -18.98M |
| December 31, 2023 | -13.39M |
| September 30, 2023 | -12.19M |
| June 30, 2023 | -19.84M |
| March 31, 2023 | -16.83M |
| December 31, 2022 | -12.93M |
| September 30, 2022 | -21.83M |
| June 30, 2022 | -26.18M |
| March 31, 2022 | -33.71M |
| December 31, 2021 | -50.79M |
| Date | Value |
|---|---|
| September 30, 2021 | -26.01M |
| June 30, 2021 | -27.52M |
| March 31, 2021 | -18.41M |
| December 31, 2020 | -21.86M |
| September 30, 2020 | -16.00M |
| June 30, 2020 | -24.10M |
| March 31, 2020 | -29.18M |
| December 31, 2019 | -33.08M |
| September 30, 2019 | -32.84M |
| June 30, 2019 | -34.38M |
| March 31, 2019 | -25.28M |
| December 31, 2018 | -20.42M |
| September 30, 2018 | -14.77M |
| June 30, 2018 | -12.99M |
| March 31, 2018 | -11.91M |
| December 31, 2017 | -9.146M |
| September 30, 2017 | -7.527M |
| June 30, 2017 | -5.232M |
| March 31, 2017 | -4.649M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Zevra Therapeutics, Inc. | 8.393M |
| Aclaris Therapeutics, Inc. | -21.50M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 92.10M |
| Total Expenses (Quarterly) | 123.20M |
| EPS Diluted (Quarterly) | -0.18 |
| Enterprise Value | 1.744B |
| Gross Profit Margin (Quarterly) | 83.47% |
| Profit Margin (Quarterly) | -33.77% |
| Earnings Yield | -1.13% |
| Operating Earnings Yield | 2.28% |
| Normalized Earnings Yield | 0.2456 |